What is it?
A psychoactive Sceletium botanical, not one uniform ingredient
6Kanna is the supplement-market name for Sceletium/Mesembryanthemum botanical material traditionally associated with South Africa. Product labels may describe raw plant material, fermented kanna, tinctures, powders, or standardized extracts. The human studies behind modern nootropic claims mostly use standardized extracts, so the exact form matters before comparing dose, price, or effects.
Names, aliases and forms
Mechanisms of action
Mesembrine-type alkaloids drive most mechanistic interest
3Mechanistic work links Sceletium extracts and alkaloids such as mesembrine and mesembrenone with serotonin-transporter and PDE4 activity. These mechanisms are plausible for calm or stress-response effects, but they are not proof of reliable clinical outcomes.
Not just an SSRI-style label
4Cell-model research on a high-mesembrine extract suggests monoamine release and VMAT-2/SERT-related effects rather than simple serotonin reuptake inhibition alone. That makes drug-interaction caution more important, especially for antidepressants, MAOIs, stimulants, sedatives, and mixed stacks.
Potential effects and evidence map
Human evidence for Kanna is limited and product-specific. Small trials and experimental studies of standardized Sceletium tortuosum extracts report signals for acute stress/anxiety responding, executive flexibility, and complex reactive tasks, but sample sizes are small, outcomes are mixed, and a systematic review/meta-analysis supports a cautious reading of anxiety-related claims. Mechanistic evidence is stronger than outcome evidence: mesembrine-type alkaloids influence serotonin transport, PDE4, and monoamine signaling.
Standardized Sceletium extract has limited human evidence for lowering acute laboratory stress/anxiety responding in healthy adults.
A single 25 mg standardized extract dose altered threat-circuitry markers and some stress-task responses, but functional outcomes remain uncertain.
Mood and wellbeing claims are plausible but mixed; small studies do not establish a reliable mood benefit for generic Kanna.
Cognitive-task evidence is limited to small extract-specific studies reporting executive/set-flexibility or complex reactive-task signals.
Typical dosages and timing
The dose context comes from standardized Zembrin studies, including 8 mg/day and 25 mg/day in a 3-month safety trial and 25 mg/day in several small effect studies. It is not a universal Kanna dose for raw herb, fermented products, tinctures, or unlabeled high-alkaloid extracts.
Timing & effect horizon
Some studies tested single-dose effects and others used 8-day, 3-week, or 3-month schedules, but those study designs do not establish a reliable public-facing onset, duration, The time for blood levels to fall by half during the final elimination phase.Source, or cycle length. Leave timing assumptions product- and context-specific.
Safety, side effects and risk profile
Avoid unsupervised combinations with serotonergic, monoamine-active, sedating, or stimulant medicines and supplements.
CNS-active effects can vary by extract and dose; avoid driving or combining with alcohol/sedatives until individual response is known.
Headache and nonspecific tolerability complaints have been reported, but small controlled studies did not show a strong safety signal.
GI discomfort is a plausible low-level tolerability issue and should be separated from high-dose or poorly characterized extract use.
Avoid use during pregnancy or lactation unless a qualified clinician has reviewed the exact product and context.
Legal and regulatory status depends on jurisdiction, product form, ingredient history, and marketing claims.
Most positive human findings are small, extract-specific, and not enough to validate broad nootropic marketing claims.
The small 3-month safety trial did not show major differences in vital signs, ECG, or routine labs at 8 or 25 mg/day, but it was too small to rule out rare events. Track headache, abdominal discomfort, dizziness, sleep changes, and unusual agitation or sedation when trying a new extract.
Human pregnancy and lactation safety data are not established for Kanna extracts. Because the ingredient is CNS-active and product composition varies, pregnancy and breastfeeding are avoid-or-review-first contexts.
Legal and regulatory status
Kanna may appear in supplement markets, but that is not the same as approval, import clearance, or workplace acceptance. In the United States, dietary supplements are regulated differently from drugs and are not preapproved by FDA for safety or effectiveness. Other jurisdictions may classify botanical extracts, novel foods, therapeutic claims, or psychoactive products differently.
How it compares
Human studies are small and mostly healthy-volunteer designs. The best-supported framing is limited, extract-specific potential for calm/stress response and narrow cognitive-task outcomes, not established clinical efficacy for anxiety, depression, sleep disorders, or broad productivity enhancement.
Practical buying and quality notes
- For price comparison, separate raw or fermented Kanna from standardized extracts. A useful listing should state the extract form, serving size, total extract per serving, and ideally mesembrine-type alkaloid standardization or a current COA.5
- Very low price per capsule is not meaningful if the product hides alkaloid content or mixes Kanna with caffeine, stimulants, sedatives, or other serotonergic botanicals. Compare normalized price only after checking the active amount and stack context.4
FAQ
Is Kanna the same as Zembrin?
7No. Kanna is the broad supplement-market name for Sceletium/Mesembryanthemum products. Zembrin is a standardized extract used in several human studies, so Zembrin data should not be assumed for every Kanna powder, tincture, or blend.
What Kanna dose was studied?
7The best-cited human studies used standardized extract doses around 8 to 25 mg/day, with many effect studies using 25 mg/day. That is a study context for a specific extract type, not a conversion rule for raw herb or high-alkaloid products.
How strong is the anxiety-related evidence?
12Limited. Kanna has small, extract-specific studies relevant to stress/anxiety responding in healthy adults, but the evidence is not strong enough for broad clinical anxiety claims or for generalizing to all Kanna products.
How long does Kanna last?
8Reliable public-facing duration and half-life values are not established from the current human evidence. Avoid using single-dose or multi-week study schedules as if they prove an onset, duration, or cycle length.
Can Kanna be combined with antidepressants?
3Do not combine Kanna with antidepressants, MAOIs, prescription stimulants, sedatives, alcohol, or other psychoactive stacks without qualified medical review. The concern is mechanistic overlap with serotonergic and monoamine systems plus unknown stacking safety.
References
- NCBI Taxonomy. Mesembryanthemum tortuosum, Taxonomy ID 216016. Accessed 2026-06-30.
- PubChem. Mesembrine, CID 394162. Accessed 2026-06-30.
- Harvey AL, Young LC, Viljoen AM, Gericke NP. Pharmacological actions of the South African medicinal and functional food plant Sceletium tortuosum and its principal alkaloids. Journal of Ethnopharmacology. 2011;137(3):1124-1129.
- Coetzee DD, Lopez V, Smith C. High-mesembrine Sceletium extract (Trimesemine) is a monoamine releasing agent, rather than only a selective serotonin reuptake inhibitor. Journal of Ethnopharmacology. 2016;177:111-116.
- Krstenansky JL. Mesembrine alkaloids: Review of their occurrence, chemistry, and pharmacology. Journal of Ethnopharmacology. 2017;195:10-19.
- Olatunji TL, Siebert F, Adetunji AE, Harvey BH, Gericke J. Sceletium tortuosum: A review on its phytochemistry, pharmacokinetics, biological, pre-clinical and clinical activities. Journal of Ethnopharmacology. 2022;287:114711.
- Nell H, Siebert M, Chellan P, Gericke N. A randomized, double-blind, parallel-group, placebo-controlled trial of Extract Sceletium tortuosum (Zembrin) in healthy adults. Journal of Alternative and Complementary Medicine. 2013;19(11):898-904.
- Terburg D, Syal S, Rosenberger LA, et al. Acute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus. Neuropsychopharmacology. 2013;38(13):2708-2716.
- Chiu S, Gericke N, Farina-Woodbury M, et al. Proof-of-concept randomized controlled study of cognition effects of the proprietary extract Sceletium tortuosum (Zembrin) targeting phosphodiesterase-4 in cognitively healthy subjects. Evidence-Based Complementary and Alternative Medicine. 2014;2014:682014.
- Reay J, Wetherell MA, Morton E, Lillis J, Badmaev V. Sceletium tortuosum (Zembrin) ameliorates experimentally induced anxiety in healthy volunteers. Human Psychopharmacology. 2020;35(6):e2753.
- Hoffman JR, Marcus I, Dubnov-Raz G, Gepner Y. Ergogenic effects of 8 days of Sceletium tortuosum supplementation on mood, visual tracking, and reaction in recreationally trained men and women. Journal of Strength and Conditioning Research. 2020;34(9):2476-2481.
- Gouhie FA, Rodrigues JPA, Vieira LF, Cunha CLN, Yuyama EK. Sceletium tortuosum effects on anxiety: A systematic review and meta-analysis. Brain Disorders. 2023;11:100092.
- ClinicalTrials.gov. Psychological Effects of 8 Weeks Supplementation With Sceletium Tortuosum Extract. NCT05471804. Accessed 2026-06-30.
- U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements. Accessed 2026-06-30.